Pfizer Debt to Equity Ratio 2006-2018 | PFE

Current and historical debt to equity ratio values for Pfizer (PFE) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Pfizer debt/equity for the three months ending September 30, 2018 was 0.47.
Pfizer Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2018-09-30 $33.65B $71.64B 0.47
2018-06-30 $28.94B $70.10B 0.41
2018-03-31 $31.83B $70.52B 0.45
2017-12-31 $33.54B $71.64B 0.47
2017-09-30 $34.50B $61.09B 0.57
2017-06-30 $34.19B $58.67B 0.58
2017-03-31 $36.33B $58.72B 0.62
2016-12-31 $31.40B $59.82B 0.53
2016-09-30 $30.44B $63.58B 0.48
2016-06-30 $30.46B $63.04B 0.48
2016-03-31 $27.82B $63.32B 0.44
2015-12-31 $28.74B $64.97B 0.44
2015-09-30 $29.08B $67.10B 0.43
2015-06-30 $26.73B $67.15B 0.40
2015-03-31 $29.37B $67.56B 0.44
2014-12-31 $31.54B $71.59B 0.44
2014-09-30 $31.67B $78.28B 0.41
2014-06-30 $32.27B $76.93B 0.42
2014-03-31 $27.65B $78.04B 0.35
2013-12-31 $30.46B $76.59B 0.40
2013-09-30 $31.81B $78.32B 0.41
2013-06-30 $31.53B $78.94B 0.40
2013-03-31 $31.48B $82.79B 0.38
2012-12-31 $31.04B $81.64B 0.38
2012-09-30 $31.08B $82.07B 0.38
2012-06-30 $30.87B $79.92B 0.39
2012-03-31 $33.54B $83.63B 0.40
2011-12-31 $34.93B $82.58B 0.42
2011-09-30 $35.40B $90.48B 0.39
2011-06-30 $35.72B $88.92B 0.40
2011-03-31 $35.31B $90.48B 0.39
2010-12-31 $38.41B $88.21B 0.44
2010-09-30 $39.01B $88.01B 0.44
2010-06-30 $37.77B $86.82B 0.44
2010-03-31 $38.28B $90.02B 0.43
2009-12-31 $43.19B $90.39B 0.48
2009-09-30 $32.40B $66.19B 0.49
2009-06-30 $31.86B $63.17B 0.50
2009-03-31 $21.06B $60.37B 0.35
2008-12-31 $7.96B $57.67B 0.14
2008-09-30 $7.15B $67.26B 0.11
2008-06-30 $7.25B $66.49B 0.11
2008-03-31 $8.14B $67.33B 0.12
2007-12-31 $7.31B $64.92B 0.11
2007-09-30 $6.04B $66.51B 0.09
2007-06-30 $5.78B $67.98B 0.09
2007-03-31 $4.77B $72.36B 0.07
2006-12-31 $5.55B $71.22B 0.08
2006-09-30 $5.56B $69.57B 0.08
2006-06-30 $5.45B $68.34B 0.08
2006-03-31 $6.51B $69.45B 0.09
2005-12-31 $6.35B $65.60B 0.10
2005-09-30 $5.41B $66.63B 0.08
2005-06-30 $5.52B $65.15B 0.09
2005-03-31 $6.43B $67.35B 0.10
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $259.009B $52.546B
Pfizer Inc. is a research-based, global pharmaceutical company that discovers, develops, manufactures, and markets medicines for humans and animals. The Company's diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer healthcare products. Pfizer's Animal Health business unit discovers, develops and sells products for the prevention and treatment of diseases in livestock and companion animals. It sells its products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, veterinarians, livestock producers, and grocery and convenience stores. Pfizer Inc. is headquartered in New York.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $391.677B 18.36
Merck (MRK) United States $205.072B 17.77
Novartis AG (NVS) Switzerland $203.357B 17.38
AbbVie (ABBV) United States $137.681B 12.22
Eli Lilly (LLY) United States $120.583B 21.20
Sanofi (SNY) France $113.115B 14.01
Novo Nordisk (NVO) Denmark $107.931B 17.53
AstraZeneca (AZN) United Kingdom $103.013B 12.79
GlaxoSmithKline (GSK) United Kingdom $100.041B 13.45
Bristol-Myers Squibb (BMY) United States $88.253B 14.53